- CRH chief executive tops list of deals
- Ex-GSK director sells stock awarded in 2020
- Redde Northgate chief also cashes in
In a quiet week for director deals one or two trades stood out, firstly the decision by Albert Manifold, chief executive of building materials firm CRH (CRH), to sell 58,346 shares at €51.48 last week, raising €3 million in proceeds.
CRH’s Dublin-listed shares are up 43% this year, recently hitting a multi-year high of €54, while its London quote is due to cease on 25 September after the firm moves its primary listing to New York.
The firm argues the move to Wall Street ‘will bring increased commercial, operational and acquisition opportunities for our business, further accelerating our successful integrated solutions strategy and delivering even higher levels of profitability, returns and cash for our shareholders’.
FORMER PHARMA EXEC CASHES IN OPTIONS
Meanwhile, former GSK (GSK) executive Dr Hal Barron to exercise some of the nil-cost options from his 2020 pay award and offload them in the market.
Latest Issue
- Under the radar funds. Discover the smaller collective vehicles which are putting some of their larger counterparts to shame.
- Plus, discover the dividend hero investment trusts which have increased their payouts year after year for decades and what to expect from US banks as they get set to kick off the US second-quarter earnings season.
- Investment ideas include a trust which aims to protect and grow your money and a building products group with exciting prospects.
- Also in the digital magazine: how to rework your financial plans in the wake of a divorce, what to expect from Netflix results and the latest on tariffs, Tesla and market winners and losers.
Barron, who until March 2022 was chief scientific officer and president of R&D (research and development) at GSK, cashed in 155,206 ADS (American depository shares) at an average price of $17.31 to net a comfortable $2.67 million.
After leaving the UK firm in March last year, Barron took on the role of chief executive and chairman at US cellular technology company Altos Labs.